Q3 saw 8.9% revenue growth, a 5% EBIT margin, and strong Rx sales, supported by the successful Varberg warehouse launch and efficiency gains. Net cash reached SEK 98 million, with a focus now shifting to external growth and leveraging new capacity.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.